JP4445753B2 - アミノピペリジン誘導体 - Google Patents

アミノピペリジン誘導体 Download PDF

Info

Publication number
JP4445753B2
JP4445753B2 JP2003564044A JP2003564044A JP4445753B2 JP 4445753 B2 JP4445753 B2 JP 4445753B2 JP 2003564044 A JP2003564044 A JP 2003564044A JP 2003564044 A JP2003564044 A JP 2003564044A JP 4445753 B2 JP4445753 B2 JP 4445753B2
Authority
JP
Japan
Prior art keywords
fluoro
pyrido
ethyl
piperidin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003564044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525324A (ja
JP2005525324A5 (https=
Inventor
ロバート・エイ・デインズ
ウィリアム・ヘンリー・ミラー
ニール・デイビッド・ピアソン
イズレイル・ペンドラク
マーク・アンドリュー・シーフェルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202026A external-priority patent/GB0202026D0/en
Priority claimed from GB0229824A external-priority patent/GB0229824D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005525324A publication Critical patent/JP2005525324A/ja
Publication of JP2005525324A5 publication Critical patent/JP2005525324A5/ja
Application granted granted Critical
Publication of JP4445753B2 publication Critical patent/JP4445753B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003564044A 2002-01-29 2003-01-27 アミノピペリジン誘導体 Expired - Fee Related JP4445753B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0202026A GB0202026D0 (en) 2002-01-29 2002-01-29 Compounds
GB0229824A GB0229824D0 (en) 2002-12-20 2002-12-20 Compounds
PCT/EP2003/000823 WO2003064421A1 (en) 2002-01-29 2003-01-27 Aminopiperidine derivatives

Publications (3)

Publication Number Publication Date
JP2005525324A JP2005525324A (ja) 2005-08-25
JP2005525324A5 JP2005525324A5 (https=) 2006-01-12
JP4445753B2 true JP4445753B2 (ja) 2010-04-07

Family

ID=27665357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003564044A Expired - Fee Related JP4445753B2 (ja) 2002-01-29 2003-01-27 アミノピペリジン誘導体

Country Status (6)

Country Link
US (1) US7312212B2 (https=)
EP (2) EP1470125A1 (https=)
JP (1) JP4445753B2 (https=)
AR (1) AR038240A1 (https=)
TW (1) TW200406410A (https=)
WO (1) WO2003064421A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511622A (ja) * 2002-12-18 2006-04-06 グラクソ　グループ　リミテッド 抗菌剤

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803369B1 (en) 2000-07-25 2004-10-12 Smithkline Beecham Corporation Compounds and methods for the treatment of neoplastic disease
GB0112834D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) * 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
TW200406413A (en) * 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
DE60331849D1 (de) 2002-11-05 2010-05-06 Glaxosmithkline Llc Antibakterielle wirkstoffe
ATE479683T1 (de) 2002-11-05 2010-09-15 Glaxo Group Ltd Antibakterielle mittel
AU2003294565A1 (en) 2002-12-04 2004-06-23 Glaxo Group Limited Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
FR2858619B1 (fr) * 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
US7691850B2 (en) 2004-06-15 2010-04-06 Glaxo Group Limited Antibacterial agents
US20070254872A1 (en) * 2004-07-08 2007-11-01 Glaxo Group Limited Antibacterial Agents
US7655648B2 (en) 2004-08-02 2010-02-02 Glaxo Group Limited Antibacterial agents
DE102004041163A1 (de) * 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
CA2580621A1 (en) * 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
US7648980B2 (en) * 2005-01-25 2010-01-19 Glaxo Group Limited Antibacterial agents
US7709472B2 (en) 2005-01-25 2010-05-04 Glaxo Group Limited Antibacterial agents
JP2008528598A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
JP2008528604A (ja) * 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
EP1846418A4 (en) * 2005-01-25 2009-12-23 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
NZ562034A (en) 2005-03-31 2009-10-30 Janssen Pharmaceutica Nv Bicyclic pyrazole compounds as antibacterial agents
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
CA2635126A1 (en) 2006-01-26 2007-08-02 Actelion Pharmaceuticals Ltd Tetrahydropyrane antibiotics
JP5191053B2 (ja) * 2006-02-15 2013-04-24 アクテリオン ファーマシューティカルズ リミテッド エタノールまたは１，２−エタンジオールシクロヘキシル抗生物質誘導体
WO2007100880A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
BRPI0708615A2 (pt) * 2006-03-07 2011-06-07 Array Biopharma Inc compostos de pirazol heterobicìclicos e métodos de uso
WO2007115947A1 (en) 2006-04-06 2007-10-18 Glaxo Group Limited Pyrrolo-quinoxalinone derivatives as antibacterials
EP2007377A4 (en) 2006-04-06 2011-08-17 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
US20100256124A1 (en) * 2006-06-09 2010-10-07 David Thomas Davies Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
EA015821B1 (ru) 2007-04-20 2011-12-30 Глэксо Груп Лимитед Трициклические азотсодержащие соединения в качестве антибактериальных агентов
EP2080761A1 (en) 2008-01-18 2009-07-22 Glaxo Group Limited Compounds
EP2276766A1 (en) 2008-04-15 2011-01-26 Actelion Pharmaceuticals Ltd. Tricyclic antibiotics
WO2010043714A1 (en) 2008-10-17 2010-04-22 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials
CN102232078B (zh) * 2008-12-12 2014-07-16 埃科特莱茵药品有限公司 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物
ES2561631T3 (es) 2009-01-15 2016-02-29 Glaxo Group Limited Compuestos de naftiridin-2(1H)-ona útiles como agentes antibacterianos
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9059778B2 (en) * 2011-01-07 2015-06-16 Integrated Device Technology Inc. Frequency domain compression in a base transceiver system
JP5918624B2 (ja) * 2012-05-18 2016-05-18 東ソ−・エフテック株式会社 光学活性含フッ素５，６−ジヒドロピリドン誘導体及びその製造方法
CN102702080B (zh) * 2012-06-21 2014-02-19 扬州氟药科技有限公司 一种3-三氟甲基哌啶衍生物的制备方法
WO2016004297A1 (en) * 2014-07-02 2016-01-07 Board Of Regents, The University Of Texas System Novel inhibitors of trypanosoma brucei methionyl t-rna synthetase (tb metrs) for the treatment of african trypanosomiasis
JP6546654B2 (ja) 2014-08-22 2019-07-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 淋菌感染を治療するための三環式含窒素化合物
UY36851A (es) 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas
CN114957114A (zh) * 2021-02-26 2022-08-30 冷志 一种4-溴-3-氯-7-甲氧基喹啉的合成方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE330945C (de) 1918-06-11 1920-12-21 Ver Chininfabriken Zimmer & Co Verfahren zur Darstellung von Chinolylketonen
GB1345872A (en) 1970-09-03 1974-02-06 Wyeth John & Brother Ltd Amino-and acylamino-pyridine and hydropyridine derivatives
BE786529A (fr) 1971-07-23 1973-01-22 Ciba Geigy Nouveaux derives de la diazepine et procedes pour leur preparation
US3989691A (en) 1973-01-05 1976-11-02 Princeton University Preparation of cinchona alkaloid intermediates
GB1537867A (en) 1977-07-04 1979-01-04 Wyeth John & Brother Ltd Process for preparing 4-acylamino-piperidine derivatives
FR2471981A1 (fr) 1979-12-21 1981-06-26 Pharmindustrie Nouveaux derives de la (piperidyl-4)-2 (quinolyl-4)-1 ethanone, produits intermediaires et procedes pour leur preparation, et leur utilisation comme medicaments
FR2495470A1 (fr) 1980-12-05 1982-06-11 Pharmindustrie Nouveaux medicaments a base de derives de (quinolyl-4)-1 (piperidyl-4)-2 ethanol ou (quinolyl-4)-1 (piperidyl-4)-3 propanol
US4925877A (en) 1986-02-25 1990-05-15 Zaidanhojin Biseibutsu Kagaku Kenkyukai Physiologically active erbstatin analogue compounds and compositions
JP2539504B2 (ja) 1987-03-11 1996-10-02 鐘淵化学工業株式会社 ヒドロキシスチレン誘導体
ZA899436B (en) 1988-12-12 1990-08-29 Ciba Geigy Piperidine derivatives
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
EP0541486A1 (de) 1991-11-07 1993-05-12 Ciba-Geigy Ag Polycyclische Konjugate
KR100330553B1 (ko) 1993-10-01 2002-11-27 노파르티스 아게 약물학적활성피리딘유도체및그의제조방법
JPH07179407A (ja) 1993-11-12 1995-07-18 Green Cross Corp:The 新規縮合環系化合物またはその塩、およびその医薬用途
HUT76853A (en) 1994-11-14 1997-12-29 Warner Lambert Co 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
KR19990008051A (ko) 1995-04-26 1999-01-25 히라타다다시 라디시콜 유도체
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6077857A (en) 1995-11-13 2000-06-20 Smithkline Beecham Corporation Hemoregulatory compounds
US5707990A (en) * 1996-01-30 1998-01-13 Ortho Pharmaceutical Corporation 2-substituted amino and thio alkyl benzoxazine antimicrobial agents
AU2898297A (en) 1996-05-24 1998-01-05 Novartis Ag Use of substance p antagonists for treating social phobia
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DE69908555T2 (de) 1998-01-26 2004-05-06 Smithkline Beecham P.L.C., Brentford Chinolinderivate als antibakterielles arzneimittel
GB9822440D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
GB9822450D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
EP1144404A1 (en) 1999-01-20 2001-10-17 Smithkline Beecham Plc Piperidinylquinolines as protein tyrosine kinase inhibitors
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
US6403610B1 (en) 1999-09-17 2002-06-11 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation and the compositions which comprise them
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6803369B1 (en) 2000-07-25 2004-10-12 Smithkline Beecham Corporation Compounds and methods for the treatment of neoplastic disease
CZ2003243A3 (cs) 2000-07-26 2003-09-17 Smithkline Beecham P. L. C. Aminopiperidinové chinoliny a jejich azaisosterické analogy s antibakteriální aktivitou
EP1719770A3 (en) 2000-09-21 2008-03-05 Smithkline Beecham Plc Quinoline derivatives as antibacterials
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
US6603005B2 (en) 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
GB0031086D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
FR2822154B1 (fr) 2001-03-13 2005-10-21 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
US6602884B2 (en) 2001-03-13 2003-08-05 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US20030203917A1 (en) 2001-07-25 2003-10-30 Smithkline Beecham Corporation And Smithkline Beecham P.L.C. Compounds and methods for the treatment of neoplastic disease
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
WO2004035569A2 (de) 2002-10-10 2004-04-29 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
DE60331849D1 (de) 2002-11-05 2010-05-06 Glaxosmithkline Llc Antibakterielle wirkstoffe
ATE479683T1 (de) 2002-11-05 2010-09-15 Glaxo Group Ltd Antibakterielle mittel
AU2003294565A1 (en) 2002-12-04 2004-06-23 Glaxo Group Limited Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
TW200427688A (en) 2002-12-18 2004-12-16 Glaxo Group Ltd Antibacterial agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511622A (ja) * 2002-12-18 2006-04-06 グラクソ　グループ　リミテッド 抗菌剤

Also Published As

Publication number Publication date
JP2005525324A (ja) 2005-08-25
EP2181996A1 (en) 2010-05-05
WO2003064421A1 (en) 2003-08-07
US20050159411A1 (en) 2005-07-21
US7312212B2 (en) 2007-12-25
TW200406410A (en) 2004-05-01
AR038240A1 (es) 2005-01-05
EP1470125A1 (en) 2004-10-27

Similar Documents

Publication Publication Date Title
JP4445753B2 (ja) アミノピペリジン誘導体
JP4508650B2 (ja) アミノピペリジン化合物、当該化合物の製法および当該化合物を含有する医薬組成物
JP4472928B2 (ja) ４位がピペリジン含有部分によって置換されたキノリンおよびその窒素化誘導体および抗菌薬としてのその使用
JP4522262B2 (ja) 化合物
US7498326B2 (en) Compounds
ES2278778T3 (es) Aminopiperidin quinolinas y sus analogos azaisostericos con actividad antibacteriana.
US7141564B2 (en) Nitrogen-containing bicyclic heterocycles for use as antibacterials
US7186730B2 (en) Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials
ES2270142T3 (es) Aminociclohexano quinolinas y sus analogos azaisostericos con actividad antibacteriana.
JP2005504747A (ja) 薬物
JP2004518661A (ja) 細菌感染の治療用ピペラジン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091030

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091222

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100118

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130122

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees